Semaglutide Dosage Chart 2026: Complete Titration Schedule

Reviewed by Dr. Donald L. Gates, MD — Bariatric Medicine since 1999

Last updated: June 2026

Why Semaglutide Uses a Titration Schedule

Semaglutide — like all GLP-1 receptor agonists — slows gastric emptying and acts on brain centers that regulate appetite. These effects are dose-dependent, meaning higher doses produce stronger appetite suppression. They also produce more pronounced gastrointestinal side effects (nausea, vomiting, diarrhea) at higher doses, particularly early in treatment.

To minimize these side effects and improve long-term tolerability, both Wegovy and Ozempic use a structured dose escalation protocol — starting well below the therapeutic dose and increasing gradually every 4 weeks. The first dose (0.25 mg for Wegovy) is explicitly a tolerability dose, not a therapeutic dose; meaningful appetite suppression begins at higher levels.

This “start low and go slow” approach is supported by the clinical trial data underlying FDA approval. The FDA’s clinical pharmacology review for Wegovy specifies that dose escalation should be delayed (not stopped) if a patient doesn’t tolerate any given step.

Wegovy (Weight Management) Dosage Chart

The following table reflects the FDA-approved titration schedule for Wegovy (semaglutide injection) for chronic weight management in adults and adolescents aged 12 and older. Source: FDA Office of Clinical Pharmacology Review, Wegovy.

Source: FDA Office of Clinical Pharmacology Review for Wegovy and Wegovy.com prescribing information. Dose escalation may be delayed at any step if side effects are not tolerable — this is clinically normal and recommended by the prescribing guidelines.

Ozempic (Type 2 Diabetes) Dosage Chart

Important: Ozempic is FDA-approved only for type 2 diabetes. This chart reflects the standard approved titration for glycemic control — it is not a weight loss dosing protocol. Ozempic should not be used for weight management as a primary indication. If weight management is your goal and you do not have type 2 diabetes, discuss Wegovy or other FDA-approved options with your physician.

Source: FDA Ozempic prescribing information and Ozempic.com dosing guide.

Note: Ozempic maximum dose is 2.0 mg weekly — lower than Wegovy’s 2.4 mg maintenance dose, and far lower than the Wegovy 7.2 mg high-dose option. These products are clinically distinct despite containing the same active ingredient.

The 7.2 mg High-Dose Wegovy Option (2026)

In March 2026, the FDA approved an extended high-dose formulation of Wegovy — 7.2 mg weekly — for adults who tolerate 2.4 mg and require further weight reduction. This approval (sometimes referred to as “Wegovy HD”) extends the dosing ceiling significantly beyond the original 2.4 mg maximum.

Important considerations for the 7.2 mg dose:

• Patients must have been on 2.4 mg for a minimum of 4 weeks before a provider can consider the 7.2 mg dose.
• Eligibility is based on clinical evaluation — it is not a dose everyone will need or should pursue.
• The same titration principles apply: the dose should only be advanced if the current dose is well tolerated.
• As a newly approved dose range, real-world tolerability and safety data will continue to accumulate in the post-market period.

Discuss with your provider whether the 7.2 mg option is relevant to your situation.

Missed Dose Protocol

Knowing what to do when you miss a dose of semaglutide is important — taking it incorrectly can cause avoidable side effects or disrupt your titration.

Wegovy and Ozempic Missed Dose Rules (Per FDA Prescribing Information)

• If your next scheduled dose is more than 2 days (48 hours) away: Take the missed dose as soon as you remember.
• If your next scheduled dose is fewer than 2 days (48 hours) away: Skip the missed dose entirely. Take your next dose on the regularly scheduled day.
• Never double-dose: Do not take two doses in the same week to make up for a missed one.
• If you miss multiple weeks in a row: Contact your provider. Depending on how many weeks were missed, your prescriber may recommend going back to a lower dose to avoid side effects when restarting.

Practical tip: Set a recurring weekly reminder on your phone — same day, same time each week. Consistency reduces the likelihood of missed doses and supports steady medication levels.

Adjusting or Slowing Your Titration

The Wegovy prescribing information explicitly states: “If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.” This is a clinical instruction, not a failure state. Many patients — particularly those with heightened GI sensitivity — benefit from spending 8 weeks at a given step rather than 4.

When Titration Should Be Paused or Slowed

• Persistent moderate-to-severe nausea: If you are losing sleep, unable to work, or significantly limiting food/fluid intake due to nausea, this dose should be held for an additional 4 weeks before escalating.
• Vomiting more than 3 times per week: Discuss with your provider before advancing.
• Significant constipation or diarrhea that is disrupting daily functioning.
• Any clinical event warranting evaluation (pancreatitis concern, gallbladder symptoms, significant cardiovascular change).

Should You Ever Step Down to a Lower Dose?

If you cannot tolerate the recommended 2.4 mg maintenance dose, the prescribing information allows for a temporary reduction to 1.7 mg weekly (for up to 4 weeks), after which the attempt to return to 2.4 mg is made. If 1.7 mg is also not tolerated, discontinuation is recommended under the current prescribing guidelines. This is a clinical decision made with your provider, not one to make unilaterally.

What Dose Do Most Patients End Up On?

In clinical trials and real-world practice, most patients who complete the Wegovy titration schedule reach and maintain the 2.4 mg dose. A meaningful minority — particularly those with pre-existing GI conditions or heightened sensitivity — remain at 1.7 mg as their long-term maintenance dose and still achieve clinically significant weight loss.

Some patients reach a plateau at 1.0 or 1.7 mg in terms of weight loss response, even if they tolerate higher doses. Dose escalation is not always the primary lever — dietary habits, sleep, stress, and activity level all interact with how the medication works.

For context on what to expect over time, see our first 30 days on semaglutide guide, our guide on preserving muscle on GLP-1, and our explainer on what happens when you stop GLP-1 therapy.

When to Consider Switching to Tirzepatide

Some patients who have been on semaglutide (Wegovy) reach a plateau in weight loss despite reaching their maintenance dose and making lifestyle adjustments. In these situations, a conversation about switching to tirzepatide (Zepbound) may be appropriate.

Reasons a provider might consider transitioning from semaglutide to tirzepatide:

• Adequate tolerability of semaglutide but insufficient weight loss response at maximum tolerated dose
• Patient preference to try a dual GIP/GLP-1 mechanism given the head-to-head trial data from SURMOUNT-5
• Changes in comorbidities or insurance coverage that make tirzepatide a better fit

Switching medications requires clinical evaluation — including a review of your current dose, duration of therapy, and side effect history. It is not a step to take based on online comparison charts alone. See our full semaglutide vs. tirzepatide comparison guide for a detailed breakdown.

Also consider our GLP-1 microdosing explainer if you are exploring lower-dose approaches for tolerability reasons.

Frequently Asked Questions

What is the highest dose of semaglutide?

As of 2026, the highest FDA-approved dose of injectable semaglutide for weight management is 7.2 mg weekly (Wegovy, approved March 2026), for adults who have tolerated the 2.4 mg maintenance dose for at least 4 weeks and need further weight reduction. For type 2 diabetes management with Ozempic, the maximum dose is 2.0 mg weekly. The oral semaglutide pill (Wegovy pill) has a maximum approved dose of 25 mg daily — a separate formulation.

How long does it take to reach the maintenance dose on Wegovy?

Following the standard titration schedule, patients reach the 2.4 mg maintenance dose at week 17 — approximately 4 months after starting. If titration is slowed due to side effects (delaying any step by 4 additional weeks), the timeline extends proportionally. A patient who takes 8 weeks at each step would reach 2.4 mg around week 33. This is clinically acceptable and often results in better long-term tolerability.

Can I skip dose increases if I’m already losing weight at a lower dose?

Technically you can stay at a lower dose if you are tolerating it well and achieving satisfactory weight loss — the goal of titration is both efficacy and tolerability. However, discuss this with your prescriber before deciding to hold at a given dose long-term. The therapeutic effect of GLP-1 medications is generally higher at higher doses, and staying at a sub-maintenance dose indefinitely may result in plateauing sooner. Your provider can help evaluate whether continuing to escalate is in your best interest.

What happens if I accidentally inject too much semaglutide?

If you believe you have taken more than your prescribed dose, contact your healthcare provider or a poison control center (1-800-222-1222 in the U.S.) promptly. Excessive dosing may result in severe nausea, vomiting, diarrhea, and hypoglycemia (particularly if you also take diabetes medications). Pre-filled Wegovy pens are designed to deliver fixed doses to reduce the risk of overdose.

Can I change the day of the week I take my injection?

Yes. According to the Ozempic and Wegovy prescribing information, you can change your weekly injection day as long as at least 2 days (48 hours) have passed since your last dose.

What if I’ve been on the same dose for months and stopped losing weight?

Weight loss plateaus are common and do not necessarily mean the medication has stopped working — it may be maintaining your current weight. Options to discuss with your provider include: advancing to the next dose tier if you haven’t reached maintenance, optimizing dietary composition, increasing activity level, or evaluating whether a medication change (including tirzepatide) might be appropriate. See our guide on stopping GLP-1 therapy for context on why continuing therapy matters even during plateaus.

Does Scale Solutions manage my dosing schedule?

Yes. Dr. Gates and the Scale Solutions team work with each patient on an individualized titration plan, monitor your response at follow-up visits, and adjust your schedule based on how you’re tolerating each dose. We do not simply issue a prescription and disappear — ongoing clinical support is part of the program.